Palmetto Peptides Complete Guide to the Research Peptide Ipamorelin
IMPORTANT DISCLAIMER: All content on this page is intended strictly for educational and scientific research purposes. Ipamorelin is a research chemical that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body for use in humans or animals. Palmetto Peptides sells Ipamorelin exclusively for in vitro (laboratory cell-based) and preclinical research use only. Nothing in this guide constitutes medical advice, and this content should not be interpreted as encouraging, recommending, or implying any use of this compound outside of a licensed research setting. Always comply with all applicable federal, state, and local laws and regulations.
Palmetto Peptides Complete Guide to the Research Peptide Ipamorelin
Last Updated: March 27, 2026 | Reading Time: Approximately 18 minutes | Author: Palmetto Peptides Research Team
Quick Answer: What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (a man-made chain of exactly five amino acids) that has been studied extensively in preclinical research as a selective growth hormone secretagogue (a compound that stimulates growth hormone release). First described in peer-reviewed literature in the late 1990s, it is notable among growth hormone secretagogues for its apparent selectivity in preclinical models, meaning published studies suggest it stimulates growth hormone release with less observed impact on other hormonal pathways compared to similar compounds.
It is classified as a research chemical and is not approved by the FDA for any use in humans or animals. All Ipamorelin available through Palmetto Peptides is sold exclusively for in vitro and preclinical scientific research.
Table of Contents
- Background and History of Ipamorelin
- Molecular Structure and Biochemistry
- How the Growth Hormone Axis Works (Plain Language Explainer)
- Ipamorelin's Mechanism of Action in Research Models
- Selectivity Profile: How Ipamorelin Compares to Other GH Secretagogues
- Overview of Preclinical Research Findings
- Ipamorelin and Bone Density Research
- Ipamorelin and Metabolic Research
- Ipamorelin Research in GH Pulse Studies
- Ipamorelin vs. Related Research Peptides
- Research-Grade Ipamorelin: Quality and Sourcing
- Legal Status and Regulatory Overview
- Frequently Asked Questions
- Peer-Reviewed Citations
- Disclaimer
Background and History of Ipamorelin
The story of Ipamorelin starts with a broader category of molecules called growth hormone secretagogues (GHS), which are compounds that stimulate the pituitary gland to release growth hormone (GH). The scientific interest in these compounds goes back to the 1970s and accelerated significantly when researchers identified the ghrelin receptor (officially called GHSR-1a) as a key molecular target.
Early growth hormone secretagogues, such as GHRP-2 and GHRP-6, demonstrated strong GH-releasing activity in animal models, but they also appeared to influence other hormonal pathways, including the release of cortisol and prolactin. From a research perspective, this created noise in experiments and made it harder to study GH-specific effects in isolation.
Ipamorelin emerged from this context as a next-generation research tool. It was first described in peer-reviewed literature by Raun et al. in 1998, in a landmark study published in the journal Endocrinology. That study characterized Ipamorelin as a selective growth hormone secretagogue with a distinct profile compared to its predecessors. Specifically, Raun and colleagues observed that in their rat and swine models, Ipamorelin stimulated GH release while showing substantially less stimulation of cortisol and ACTH (adrenocorticotropic hormone) than GHRP-6, which was a significant finding for the research community at the time.
Since that initial characterization, Ipamorelin has become a widely referenced tool compound in preclinical research focused on the GH/IGF-1 axis, bone metabolism, and metabolic signaling. It is commercially available in research-grade form from suppliers including Palmetto Peptides, where it is subject to rigorous purity testing.
Molecular Structure and Biochemistry
Amino Acid Sequence and Chemical Identity
Ipamorelin is a pentapeptide, meaning it is built from a chain of five amino acids. Its amino acid sequence is:
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Let's break that down in plain terms:
- Aib (alpha-aminoisobutyric acid): A non-natural, modified amino acid that helps the peptide resist enzymatic degradation in biological systems
- His (histidine): A standard amino acid
- D-2-Nal (D-2-naphthylalanine): A synthetic, non-natural amino acid incorporating a naphthalene ring structure
- D-Phe (D-phenylalanine): The "D" form (mirror image) of phenylalanine, another structural modification that improves stability
- Lys-NH2 (lysine amide): Lysine with an amide group at the C-terminus, which further stabilizes the molecule
The inclusion of non-natural amino acids and the amide C-terminus are intentional design choices. Natural peptides are broken down rapidly by peptidases (enzymes that chop up peptide chains) in biological systems. By incorporating these structural modifications, Ipamorelin is engineered to have greater resistance to enzymatic degradation, making it more useful as a research probe.
| Property | Value |
|---|---|
| Molecular Formula | C38H49N9O5 |
| Molecular Weight | 711.87 g/mol |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 170851-70-4 |
| Purity (research grade) | Greater than or equal to 98% (HPLC verified) |
| Appearance | White to off-white lyophilized powder |
| Storage (research use) | Typically -20°C, protected from light |
Table 1: Key physicochemical properties of Ipamorelin for research reference.
Why Structure Matters in Peptide Research
One of the recurring themes in peptide research is the relationship between structure and selectivity. Small changes in an amino acid sequence or the addition of modified residues can dramatically change which receptor a peptide binds to, how strongly it binds, and what downstream effects it triggers. Ipamorelin's specific structure is what gives it the selectivity profile that makes it a useful research tool.
To put it simply: the shape of a peptide determines which "lock" (receptor) its "key" (molecular structure) can fit. Ipamorelin's shape appears well-suited to the ghrelin receptor, while fitting less well into the receptors that trigger cortisol or prolactin release.
How the Growth Hormone Axis Works: A Plain Language Explainer
Before diving into Ipamorelin's specific mechanism, it helps to understand the broader hormonal system it interacts with. This section is designed to be accessible even if you don't have a background in endocrinology.
The Hypothalamus-Pituitary Axis: Your Body's Hormonal Command Center
Think of the hypothalamus (a small region at the base of the brain) as the command center, and the pituitary gland (a pea-sized gland just below it) as the factory that executes the orders. Together, they regulate the release of several important hormones, including growth hormone.
Here is a simplified version of how GH release is controlled:
- The hypothalamus produces GHRH (Growth Hormone Releasing Hormone), which tells the pituitary to release GH.
- The hypothalamus also produces somatostatin, which acts as the brake, telling the pituitary to stop releasing GH.
- The stomach produces a hormone called ghrelin, which acts through the GHSR-1a receptor to stimulate GH release and also signals hunger.
- The pituitary's somatotroph cells integrate these signals and release GH in pulses.
- GH then travels through the bloodstream and triggers the liver to produce IGF-1 (Insulin-like Growth Factor 1), which mediates many of GH's effects on tissues.
This whole system is called the GH/IGF-1 axis. It plays a central role in growth during development, as well as in metabolism, body composition, and tissue repair processes studied in basic research.
HYPOTHALAMUS
|
|---> GHRH (stimulates GH release)
|---> Somatostatin (inhibits GH release)
|
PITUITARY GLAND (Somatotroph Cells)
|
|---> Growth Hormone (GH) [released in pulses]
|
LIVER + PERIPHERAL TISSUES
|
|---> IGF-1 (mediates many GH effects in research models)
STOMACH
|---> Ghrelin (acts on GHSR-1a receptor to stimulate GH release)
GHSR-1a Receptor
|
|---> Ipamorelin binds here in research modelsFigure 1: Simplified diagram of the GH/IGF-1 axis and the point of Ipamorelin's action in preclinical research.
What Is a Growth Hormone Secretagogue?
A secretagogue is any compound that causes another substance to be secreted (released). A growth hormone secretagogue is therefore a compound that stimulates the release of growth hormone. This can happen through different receptor targets. Ipamorelin belongs to the class of ghrelin receptor agonists, meaning it activates the same receptor that the natural hunger hormone ghrelin uses.
Ipamorelin's Mechanism of Action in Research Models
Receptor Binding: The Starting Point
Ipamorelin's primary mechanism of action, as characterized in published preclinical research, is as an agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a), commonly known as the ghrelin receptor.
In plain terms: Ipamorelin fits into and activates the ghrelin receptor. When this receptor is activated in research models, it initiates a signaling cascade inside the cell.
The Downstream Signaling Cascade
When Ipamorelin activates GHSR-1a in research systems, it triggers a G-protein coupled signaling pathway. Here is what that pathway looks like in simplified steps:
- Ipamorelin binds to GHSR-1a on the surface of somatotroph cells in the pituitary.
- This activates a G-protein (specifically Gq/11) inside the cell.
- The G-protein activates an enzyme called phospholipase C (PLC).
- PLC generates a second messenger called IP3 (inositol trisphosphate).
- IP3 triggers the release of calcium ions from intracellular stores.
- The rise in intracellular calcium triggers the secretion of GH from the somatotroph cell.
This cascade is well documented in G-protein coupled receptor (GPCR) pharmacology, and Ipamorelin has been used as a research tool to study this pathway specifically.
Why Selectivity Matters in GH Research
One of the challenges in studying the GH axis is that many compounds that stimulate GH release also trigger the release of other hormones, particularly cortisol and prolactin. Cortisol is a stress hormone that can itself affect body composition, immune function, and metabolism in research models. Prolactin affects reproductive biology. When a research compound stimulates multiple hormonal pathways simultaneously, it becomes difficult to attribute observed effects to GH release specifically.
This is why Ipamorelin's apparent selectivity profile, first described by Raun et al. (1998), was scientifically significant. It offered researchers a more targeted tool for studying GH-related biology without as many confounding hormonal variables.
Selectivity Profile: What the Research Shows
The Key Finding from Raun et al. (1998)
The foundational paper characterizing Ipamorelin was published in Endocrinology in 1998. In that study, conducted in rats and young swine, researchers compared the effects of Ipamorelin, GHRP-6, and GHRH on GH release as well as on cortisol, ACTH (a hormone that stimulates cortisol production), and prolactin levels.
Key findings from this preclinical study:
- Ipamorelin stimulated GH release in a dose-dependent manner in both rat and swine models.
- At doses that produced robust GH release, Ipamorelin showed significantly less stimulation of cortisol and ACTH compared to GHRP-6.
- Prolactin levels were also less affected by Ipamorelin compared to GHRP-6 at equivalent GH-releasing doses.
- The authors characterized Ipamorelin as "the first GHRP receptor agonist with a selectivity for GH release similar to that displayed by GHRH."
It is important to emphasize that these were preclinical animal studies and the findings cannot be extrapolated to predict effects in humans.
Comparison Chart: Ipamorelin vs. Other GH Secretagogues in Preclinical Research
| Compound | GH Stimulation | Cortisol Stimulation | Prolactin Stimulation | Research Notes |
|---|---|---|---|---|
| Ipamorelin | Strong | Minimal (preclinical) | Minimal (preclinical) | High selectivity profile observed in animal models |
| GHRP-6 | Strong | Moderate to High | Moderate | Earlier generation; less selective |
| GHRP-2 | Strong | Moderate | Moderate | Similar selectivity concerns as GHRP-6 |
| CJC-1295 | Strong | Minimal | Minimal | Acts on GHRH receptor, not ghrelin receptor; different mechanism |
| Sermorelin | Moderate | Minimal | Minimal | GHRH analog; acts upstream of Ipamorelin's target |
Table 2: Comparative selectivity profiles of common GH secretagogues as characterized in preclinical literature. All data reflects findings from animal model studies only.
Research Note: The selectivity data in Table 2 reflects findings from preclinical (animal) research. These observations may not translate to human biology. This table is provided for educational and research reference purposes only.
For researchers interested in related peptides, Palmetto Peptides also provides research-grade CJC-1295, GHRP-6, GHRP-2, and Sermorelin for comparative research applications.
Overview of Preclinical Research Findings
Summary
Ipamorelin has been the subject of multiple preclinical studies since its initial characterization in 1998. Research has been conducted across several areas, including GH axis biology, bone physiology, metabolism, and gastrointestinal function. Below is a structured overview of the key research areas and findings, with peer-reviewed citations provided in the citations section.
Research Summary: Ipamorelin has demonstrated activity as a selective GHSR-1a agonist in multiple preclinical models. Published studies have explored its effects on GH pulse patterns, bone mineral density, and fat metabolism in animal systems. No human clinical trials have been completed or approved.
Ipamorelin and Bone Density Research
What the Preclinical Studies Found
One area that has received notable attention in the Ipamorelin research literature is bone physiology. Several animal studies have investigated whether GH secretagogues, including Ipamorelin, might influence bone density and bone formation parameters.
A particularly cited study by Svensson et al. examined GH secretagogues in aged rats and evaluated changes in bone mineral content and bone mineral density. The rationale for this line of research stems from the well-established relationship between the GH/IGF-1 axis and bone remodeling, a process by which old bone tissue is replaced with new bone tissue. In animal models, growth hormone and IGF-1 have been shown to play important roles in this process.
In preclinical rat studies, Ipamorelin administration was associated with changes in markers of bone turnover and bone mineral density measurements. These findings have generated interest in the compound as a research tool for studying GH-mediated bone biology, though it bears emphasizing that all such findings are from animal research and do not constitute evidence of therapeutic benefit.
Why This Research Area Matters Scientifically
Understanding the molecular pathways that regulate bone density is a significant area of basic science research. The GH/IGF-1 axis is one of several signaling networks that influence osteoblast (bone-building cell) and osteoclast (bone-resorbing cell) activity. Research tools that can selectively probe this axis, as Ipamorelin is designed to do, are useful for delineating which specific signals are responsible for observed effects on bone.
Researchers interested in bone biology and GH-related signaling may also find relevant research peptides at Palmetto Peptides, including IGF-1 LR3 and BPC-157, which have been studied in related tissue repair and growth contexts.
Ipamorelin and Metabolic Research
GH Secretagogues and Body Composition Models
The GH/IGF-1 axis has long been recognized as playing a role in metabolic processes, including the partitioning of nutrients between fat storage and lean tissue. In basic science research, GH itself has been shown to promote lipolysis (the breakdown of stored fat) and to influence glucose metabolism in preclinical models.
As a tool for studying GH secretion, Ipamorelin has been used in some metabolic research contexts. Studies in rodent models have examined whether stimulating GH release via GHSR-1a agonism influences body fat composition and lean mass parameters. These studies are conducted within controlled laboratory settings and are intended to explore the basic biology of the GH axis rather than to develop clinical treatments.
The GH Pulse Research Application
One important aspect of GH physiology that researchers have studied using Ipamorelin is GH pulsatility. In normal physiology (as characterized in animal research models), GH is not released continuously but rather in pulses, with peaks typically occurring at certain times. The pattern of these pulses influences how downstream tissues respond.
Because Ipamorelin stimulates GH release acutely in research models without producing the sustained suppression of endogenous GH patterns that some other compounds do, it has been useful as a tool for studying pulsatile GH dynamics in controlled preclinical experiments.
Ipamorelin Research in GH Pulse Studies
Why GH Pulsatility Is an Active Research Area
GH pulsatility research investigates the timing, amplitude, and frequency of growth hormone release pulses and how those characteristics affect physiological outcomes in animal models. It is an area where research peptides like Ipamorelin serve as important tool compounds.
The ghrelin receptor system has been shown in preclinical models to be an important modulator of GH pulse amplitude. By using a selective ghrelin receptor agonist like Ipamorelin, researchers can study how GHSR-1a activation specifically contributes to GH pulse characteristics without activating other pathways that also influence GH secretion.
Supporting Research Articles
For deeper dives into related topics, explore these supporting research resources from Palmetto Peptides:
- How Growth Hormone Secretagogues Work: A Research Overview
- GHRP-6 vs. Ipamorelin: Comparing GH Secretagogue Research Profiles
- The Ghrelin Receptor (GHSR-1a) in Preclinical Research
- CJC-1295 and Ipamorelin in GH Axis Research
- Understanding IGF-1: The GH Downstream Mediator
- Bone Mineral Density and the GH/IGF-1 Axis in Animal Models
Ipamorelin vs. Related Research Peptides
Choosing the Right Tool Compound for Your Research
Researchers studying the GH axis have several peptide tool compounds to choose from, each with distinct receptor targets, half-lives, and selectivity profiles. Understanding these differences is essential for designing experiments that answer the specific questions being investigated.
Ipamorelin vs. CJC-1295
CJC-1295 is a GHRH analog, meaning it acts on a completely different receptor (the GHRH receptor) than Ipamorelin (which acts on GHSR-1a). These two compounds can be useful for comparative studies examining whether a particular GH-related effect is mediated through the ghrelin receptor pathway or the GHRH receptor pathway. Research involving both compounds can help delineate receptor-specific contributions to observed biological effects.
Palmetto Peptides offers research-grade CJC-1295 with documentation available for review.
Ipamorelin vs. GHRP-6
GHRP-6 was one of the earlier-generation ghrelin receptor agonists used in preclinical research. As discussed in the selectivity section above, published research suggests Ipamorelin has a more selective profile with less cortisol and prolactin stimulation in animal models. For researchers specifically interested in isolating GH-specific effects, this selectivity difference can be scientifically meaningful.
Research-grade GHRP-6 is also available at Palmetto Peptides for comparative research.
Ipamorelin vs. Sermorelin
Sermorelin is a truncated analog of GHRH and works upstream of Ipamorelin by acting on the GHRH receptor rather than the ghrelin receptor. It mimics the natural GHRH signal rather than the ghrelin signal. Comparative research using both Sermorelin and Ipamorelin can be useful for studying the relative contributions of each receptor pathway to GH secretion patterns.
Palmetto Peptides carries research-grade Sermorelin for laboratory use.
Quick Comparison Summary
| Feature | Ipamorelin | CJC-1295 | GHRP-6 | Sermorelin |
|---|---|---|---|---|
| Receptor Target | GHSR-1a | GHRH Receptor | GHSR-1a | GHRH Receptor |
| Peptide Length | 5 amino acids | 30 amino acids | 6 amino acids | 29 amino acids |
| GH Selectivity (preclinical) | High | High | Moderate | High |
| Cortisol Stimulation (preclinical) | Low | Low | Moderate to High | Low |
| Research Application | GH pulse studies, selectivity research | GH axis stimulation, metabolic models | Comparative GH studies | GHRH pathway studies |
Table 3: Comparative overview of GH-related research peptides available at Palmetto Peptides. For research reference only.
Research-Grade Ipamorelin: Quality and Sourcing
Why Purity Matters in Peptide Research
The reproducibility of research findings depends heavily on the quality of the reagents used. Impure or degraded peptides can produce inconsistent results, introduce artifacts, and confound data interpretation. This is why purity verification is a non-negotiable standard in professional peptide research supply.
Palmetto Peptides provides Ipamorelin at research grade purity (98% or greater), verified through:
- HPLC Analysis (High Performance Liquid Chromatography): A method that separates, identifies, and quantifies components in a mixture. HPLC purity testing confirms that at least 98% of what you receive is the target peptide.
- Mass Spectrometry (MS): Confirms the exact molecular mass of the compound, verifying that the correct peptide was synthesized and not a closely related contaminant.
- Third-Party Certificate of Analysis (CoA): Independently issued documentation confirming analytical results. Available for all Palmetto Peptides products.
Storage Recommendations for Research Ipamorelin
Proper storage is essential for maintaining peptide integrity. General research guidelines for lyophilized (freeze-dried) peptides like Ipamorelin include:
- Store lyophilized powder at or below -20°C (-4°F)
- Protect from light
- Minimize freeze-thaw cycles once reconstituted
- Once reconstituted in sterile water or bacteriostatic water, store at 4°C and use within an appropriate research timeframe per your laboratory's SOPs
These storage guidelines are provided for research reference purposes only.
Where to Purchase Research-Grade Ipamorelin
Palmetto Peptides offers research-grade Ipamorelin with full documentation and third-party certificates of analysis. All purchases are subject to Palmetto Peptides' terms of service, which strictly limit product use to in vitro and preclinical research applications only.
Legal Status and Regulatory Overview
FDA Regulatory Classification
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA) for any therapeutic, preventive, or diagnostic use in humans or animals. It is classified as a research chemical and does not hold Investigational New Drug (IND) status for any active clinical application at the time of this guide's publication.
In the United States, research chemicals are legally available for purchase and use in controlled scientific research settings, provided they are not controlled substances under the Controlled Substances Act and are not being sold for human or animal consumption. Ipamorelin does not appear on the federal Schedule of Controlled Substances as of the date of this publication.
Regulatory Considerations for Researchers
Researchers considering using Ipamorelin in preclinical in vivo studies should be aware of the following general regulatory considerations:
- Institutional Animal Care and Use Committee (IACUC) approval is required for any in vivo animal research in the United States.
- Researchers are responsible for ensuring compliance with all applicable institutional, state, and federal regulations governing research chemical use.
- Ipamorelin should be handled using appropriate laboratory safety practices per your institution's guidelines.
Anti-Doping Classification
The World Anti-Doping Agency (WADA) has classified growth hormone secretagogues, including Ipamorelin, as prohibited substances in competitive sports. This is relevant context for the research community, as it reflects international recognition of this compound class's biological activity, and underscores why it is reserved for controlled research rather than general use.
No Human or Veterinary Use
Palmetto Peptides explicitly states that all peptide products, including Ipamorelin, are sold strictly for in vitro and preclinical research purposes only. These products are not intended for use in humans or animals outside of a properly approved and regulated research setting. Any such use would be outside the intended purpose of the product and contrary to applicable regulations.
Supporting Research Articles
- Ipamorelin Mechanism of Action
- Ipamorelin vs GHRP-2 and GHRP-6: Comparative Analysis
- Key Animal Studies on Ipamorelin
- Reconstitution Guide for Ipamorelin Research Peptide
- Storage and Stability of Ipamorelin Research Peptides
- Ipamorelin and CJC-1295 Combination Research
- Purity Testing and Quality Control for Ipamorelin
- Chemical Structure and Synthesis of Ipamorelin
- Pharmacokinetics of Ipamorelin in Preclinical Models
- Sourcing High-Purity Ipamorelin for Scientific Research
- Development History of Ipamorelin
Frequently Asked Questions
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (a chain of five amino acids) that acts as a selective growth hormone secretagogue in preclinical research. It binds to the ghrelin receptor (GHSR-1a) and has been studied in animal models for its ability to stimulate growth hormone release with apparent selectivity compared to earlier-generation compounds. It is not approved by the FDA for use in humans or animals and is sold exclusively for laboratory research purposes.
How does Ipamorelin work at the molecular level?
Ipamorelin binds to the ghrelin receptor (GHSR-1a) in in vitro and in vivo research models. This binding triggers a G-protein coupled signaling cascade that ultimately leads to the release of growth hormone from somatotroph cells in the pituitary gland. Published preclinical research has shown that this mechanism appears to be selective, with less observed stimulation of cortisol, prolactin, or ACTH compared to some other growth hormone secretagogues in animal studies.
Is Ipamorelin FDA approved?
No. Ipamorelin is not approved by the U.S. Food and Drug Administration for any use in humans or animals. It is classified as a research chemical and is legally available only for in vitro and preclinical research purposes.
What is the difference between Ipamorelin and GHRP-6?
Both Ipamorelin and GHRP-6 act on the ghrelin receptor (GHSR-1a). However, published preclinical research suggests Ipamorelin demonstrates greater selectivity, with studies observing less stimulation of cortisol and prolactin compared to GHRP-6. This selectivity profile makes Ipamorelin a useful tool compound in GH-axis research when researchers want to minimize confounding hormonal variables.
What does Ipamorelin's research literature cover?
Peer-reviewed preclinical research on Ipamorelin has investigated its selectivity as a GH secretagogue, its effects on bone mineral density parameters in animal models, its influence on GH pulse patterns, and its metabolic effects in rodent studies. All published research has been conducted in controlled laboratory settings.
Where can I purchase research-grade Ipamorelin?
Research-grade Ipamorelin is available through Palmetto Peptides at palmettopeptides.com/products/ipamorelin. Palmetto Peptides provides third-party certificates of analysis and HPLC purity verification for all peptide products. Products are sold exclusively for in vitro and preclinical research use.
What purity grade is research Ipamorelin available in?
Research-grade Ipamorelin from Palmetto Peptides is available at 98%+ purity, verified by HPLC and mass spectrometry. A third-party certificate of analysis is available with each order.
Can Ipamorelin be used in humans?
No. Ipamorelin is not approved for human use by the FDA or any other regulatory body. It is sold strictly for laboratory research purposes. Palmetto Peptides' terms of service expressly prohibit the purchase of any research peptide for use in humans or animals outside of a properly approved regulatory framework.
What other peptides are related to Ipamorelin research?
Related research peptides that are commonly used in GH axis studies alongside or in comparison with Ipamorelin include CJC-1295, GHRP-6, GHRP-2, Sermorelin, and IGF-1 LR3. Each of these acts through distinct but related pathways in the GH/IGF-1 axis.
How should research-grade Ipamorelin be stored?
Research-grade lyophilized Ipamorelin should be stored at or below -20°C, protected from light. Once reconstituted, it should be kept at 4°C and used within a timeframe consistent with your laboratory's standard operating procedures. These recommendations are for research reference only.
Peer-Reviewed Citations
The following peer-reviewed publications are cited as foundational research references for the information presented in this guide. All citations are from scientific literature and are provided for educational and research reference purposes.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Romer J, Ahnfelt-Ronne I, Ohlsson C, Jansson JO. "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats." Journal of Endocrinology. 2000;165(3):569-577. doi:10.1677/joe.0.1650569
- Raun K, Svendsen O, Johansen NL, Andersen PH, Ankersen M. "Ipamorelin, a new growth hormone secretagogue: studies in rats and swine on GH-releasing and endocrine side-effects." Endocrine. 1998;9(2):113-121.
- Ankersen M, Johansen NL, Madsen K, Hansen TK, Raun K, Hansen BS, Andersen PH, Thogersen H, Nielsen KK, Peschke B, Lau J, Lundt BF, Sidelmann UG. "Discovery of a new class of functionally and structurally distinct compounds with growth hormone secretagogue properties." Journal of Medicinal Chemistry. 1998;41(19):3699-3704. doi:10.1021/jm980126l
- Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. "Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity." European Journal of Pharmacology. 2002;440(2-3):235-254. doi:10.1016/s0014-2999(02)01432-2
- Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Bhatt BG, McKelvy JF, Patchett AA, Nargund RP, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science. 1996;273(5277):974-977. doi:10.1126/science.273.5277.974
- Smith RG, Sun Y, Betancourt L, Asnicar M. "Growth hormone secretagogues: prospects and potential pitfalls." Best Practice and Research Clinical Endocrinology and Metabolism. 2004;18(3):333-347. doi:10.1016/j.beem.2004.03.002
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." European Journal of Endocrinology. 1997;136(5):445-460. doi:10.1530/eje.0.1360445
- Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cellular and Molecular Life Sciences. 1998;54(12):1316-1329. doi:10.1007/s000180050257
Final Disclaimer and Legal Notice
The information presented in this guide is intended for educational, informational, and scientific research reference purposes only. Ipamorelin is not a drug, supplement, or therapeutic agent. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for use in humans or animals.
Palmetto Peptides sells all research peptides, including Ipamorelin, exclusively for in vitro laboratory research and preclinical scientific investigation. These products are not intended for human consumption, veterinary use, or any application outside of a properly approved and regulated research context.
Nothing in this guide constitutes medical or veterinary advice. Researchers are solely responsible for ensuring their use of any compound complies with all applicable institutional, local, state, and federal laws and regulations.
If you have questions about the appropriate use of research peptides, consult your institution's regulatory and compliance office.
This guide was authored by the Palmetto Peptides Research Team and is reviewed periodically for accuracy and regulatory compliance.
Last Updated: March 27, 2026
© Palmetto Peptides. All rights reserved. For research use only.